ENXTPA:VLABiotechs
UK IXCHIQ Update Puts Valneva Vaccine Safety And Valuation In Focus
The UK's Commission on Human Medicines has issued updated recommendations on the prescribing information for Valneva's chikungunya vaccine, IXCHIQ.
The changes refine restrictions on use in specific patient groups following earlier concerns about adverse events.
The update affects how IXCHIQ can be used in the UK and reflects ongoing post marketing safety monitoring.
For investors watching Valneva (ENXTPA:VLA), this regulatory update lands at a time when the shares trade around €4.69. The...